Body Composition

Tesamorelin

Tesamorelin

The only FDA-approved peptide for visceral fat reduction

Research Status: FDA-approved (Egrifta) TH9507 Egrifta
Mechanism of Action

How it works

Tesamorelin mimics endogenous GHRH to stimulate pulsatile GH release from the anterior pituitary. It selectively reduces visceral adipose tissue, particularly HIV-associated lipodystrophy, without significantly affecting subcutaneous fat or other tissues.

Areas of Research

What the research explores

In published research, Tesamorelin has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Significantly reduces visceral (abdominal) adipose tissue
  • FDA-approved for HIV-associated lipodystrophy (Egrifta)
  • Improves triglyceride levels and cardiovascular risk factors
  • Enhances lean body composition
  • Improves cognitive function in age-related studies
  • Well-characterized safety profile from Phase III trials
Research Highlight

Tesamorelin is the only FDA-approved peptide specifically for body composition, reducing visceral fat by an average of 15-18% in Phase III clinical trials.

Safety Profile

Adverse events & gaps

FDA-approved with well-documented safety data. Potential edema, arthralgia, myalgia at higher doses.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.